CL2024002218A1 - Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico - Google Patents

Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico

Info

Publication number
CL2024002218A1
CL2024002218A1 CL2024002218A CL2024002218A CL2024002218A1 CL 2024002218 A1 CL2024002218 A1 CL 2024002218A1 CL 2024002218 A CL2024002218 A CL 2024002218A CL 2024002218 A CL2024002218 A CL 2024002218A CL 2024002218 A1 CL2024002218 A1 CL 2024002218A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
administration
antineoplastic drug
composition including
phthalazinone derivative
Prior art date
Application number
CL2024002218A
Other languages
English (en)
Spanish (es)
Inventor
Sik Lee Won
Soo Ha Kyoung
Roh Eun-Jihn
LEE Myongjae
Hong Minju
Choi Sungyeon
Eun Kim Jeong
Je In-Gyu
Yoo Yeongran
Lim Jong-Ha
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Publication of CL2024002218A1 publication Critical patent/CL2024002218A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2024002218A 2022-01-25 2024-07-23 Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico CL2024002218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263302834P 2022-01-25 2022-01-25

Publications (1)

Publication Number Publication Date
CL2024002218A1 true CL2024002218A1 (es) 2024-12-20

Family

ID=87470837

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002218A CL2024002218A1 (es) 2022-01-25 2024-07-23 Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico

Country Status (14)

Country Link
US (1) US20250120970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469051A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505381A (cg-RX-API-DMAC7.html)
KR (1) KR20240138069A (cg-RX-API-DMAC7.html)
CN (1) CN118613264A (cg-RX-API-DMAC7.html)
AU (1) AU2023210923A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249330A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002218A1 (cg-RX-API-DMAC7.html)
IL (1) IL314334A (cg-RX-API-DMAC7.html)
JO (1) JOP20240162A1 (cg-RX-API-DMAC7.html)
MA (1) MA66598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009168A (cg-RX-API-DMAC7.html)
TW (1) TW202339753A (cg-RX-API-DMAC7.html)
WO (1) WO2023144626A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
WO2021214502A1 (en) * 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) * 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형

Also Published As

Publication number Publication date
TW202339753A (zh) 2023-10-16
CA3249330A1 (en) 2023-08-03
MX2024009168A (es) 2024-08-09
JP2025505381A (ja) 2025-02-26
EP4469051A1 (en) 2024-12-04
KR20240138069A (ko) 2024-09-20
CN118613264A (zh) 2024-09-06
MA66598A1 (fr) 2024-11-29
IL314334A (en) 2024-09-01
WO2023144626A1 (en) 2023-08-03
EP4469051A4 (en) 2025-12-17
AU2023210923A1 (en) 2024-07-25
US20250120970A1 (en) 2025-04-17
JOP20240162A1 (ar) 2024-07-23

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
BR112021018169A2 (pt) Composto para o controle de diabetes de felinos
DOP2022000107A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
UY38431A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
ECSP099734A (es) Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
CO2023000194A2 (es) Administración de sulcardina para el tratamiento de fibrilación auricular aguda
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
ES3063367T3 (en) Composition having improved voluntary acceptance
MX2024009168A (es) Composicion farmaceutica que incluye derivado de ftalazinona para coadministracion con farmaco antineoplasico.
ECSP10010054A (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
BR112022020755A2 (pt) Uso de uma composição farmacêutica
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
AR067320A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias
UY38589A (es) Composición farmacéutica liofilizada de antiinflamatorio no esteroideo
CO2025014537A2 (es) Fórmula combinada que comprende sacubitrilo-valsartán e inhibidor del sglt-2 con estabilidad y velocidad de disolución mejoradas
AR123553A1 (es) Formas farmacéuticas sólidas con perfiles de disgregación mejorados
CL2021002283A1 (es) Composición farmacéutica liofilizada de antiinflamatorio no esteroideo
MX2025007429A (es) Composiciones para la prevencion y el tratamiento de la insuficiencia renal (rf)
ECSP21006974A (es) Composiciones farmacéuticas que comprenden meloxicam